|
1
|
Hino O, Kobayashi E, Nishizawa M, et al:
Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol.
121:602–605. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yamashita Y, Yokoyama M, Kobayashi E,
Takai S and Hino O: Mapping and determination of the cDNA sequence
of the Erc gene preferentially expressed in renal cell
carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem
Biophys Res Commun. 275:134–140. 2000.PubMed/NCBI
|
|
3
|
Hino O: Multistep renal carcinogenesis in
the Eker (Tsc 2 gene mutant) rat model. Curr Mol Med. 4:807–811.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang K and Pastan I: Molecular cloning of
mesothelin, a differentiation antigen present on mesothelium,
mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA.
93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hassan R, Bera T and Pastan I: Mesothelin:
a new target for immunotherapy. Clin Cancer Res. 10:3937–3942.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hassan R, Remaley AT, Sampson ML, et al:
Detection and quantitation of serum mesothelin, a tumor marker for
patients with mesothelioma and ovarian cancer. Clin Cancer Res.
12:447–453. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shiomi K, Miyamoto H, Segawa T, et al:
Novel ELISA system for detection of N-ERC/mesothelin in the sera of
mesothelioma patients. Cancer Sci. 97:928–932. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Inami K, Kajino K, Abe M, et al: Secretion
of N-ERC/mesothelin and expression of C-ERC/mesothelin in human
pancreatic ductal carcinoma. Oncol Rep. 20:1375–1380.
2008.PubMed/NCBI
|
|
9
|
Shiomi K, Hagiwara Y, Sonoue K, et al:
Sensitive and specific new enzyme-linked immunosorbent assay for
N-ERC/mesothelin increases its potential as a useful serum tumor
marker for mesothelioma. Clin Cancer Res. 14:1431–1437. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yen MJ, Hsu CY, Mao TL, et al: Diffuse
mesothelin expression correlates with prolonged patient survival in
ovarian serous carcinoma. Clin Cancer Res. 12:827–831. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Argani P, Iacobuzio-Donahue C, Ryu B, et
al: Mesothelin is overexpressed in the vast majority of ductal
adenocarcinomas of the pancreas: identification of a new pancreatic
cancer marker by serial analysis of gene expression (SAGE). Clin
Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
|
|
12
|
Atmaca A, Pauligk C, Steinmetz K,
Altmannsberger HM, Jäger E and Al-Batran SE: Prognostic impact of
phosphorylated mitogen-activated protein kinase expression in
patients with metastatic gastric cancer. Oncology. 80:130–134.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Niu Z, Zhang L, et al:
Clinicopathological significance of mesothelin expression in
invasive breast cancer. J Int Med Res. 40:909–916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawamata F, Homma S, Kamachi H, et al:
C-ERC/mesothelin provokes lymphatic invasion of colorectal
adenocarcinoma. J Gastroenterol. Mar 20–2013.(Epub ahead of
print).
|
|
15
|
Alvarez H, Rojas PL, Yong KT, et al:
Mesothelin is a specific biomarker of invasive cancer in the
Barrett-associated adenocarcinoma progression model: translational
implications for diagnosis and therapy. Nanomedicine. 4:295–301.
2008. View Article : Google Scholar
|
|
16
|
Scholler N, Fu N, Yang Y, et al: Soluble
member(s) of the mesothelin/megakaryocyte potentiating factor
family are detectable in sera from patients with ovarian carcinoma.
Proc Natl Acad Sci USA. 96:11531–11536. 1999. View Article : Google Scholar
|
|
17
|
Baba K, Ishigami S, Arigami T, et al:
Mesothelin expression correlates with prolonged patient survival in
gastric cancer. J Surg Oncol. 105:195–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Einama T, Homma S, Kamachi H, et al:
Luminal membrane expression of mesothelin is a prominent poor
prognostic factor for gastric cancer. Br J Cancer. 107:137–142.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hino O and Maeda M: Diagnostic tumor
marker of asbestos-related mesothelioma. Environ Health Prev Med.
13:71–74. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chomczynski P and Sacchi N: Single-step
method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem.
162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishikawa K, Segawa T, Hagiwara Y, Maeda M,
Abe M and Hino O: Establishment of novel mAb to human
ERC/mesothelin useful for study and diagnosis of
ERC/mesothelin-expressing cancers. Pathol Int. 59:161–166. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Onda M, Nagata S, Ho M, et al:
Megakaryocyte potentiation factor cleaved from mesothelin precursor
is a useful tumor marker in the serum of patients with
mesothelioma. Clin Cancer Res. 12:4225–4231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saeki H, Hashizume A, Izumi H, et al: The
utility of serum N-ERC/mesothelin as a biomarker of ovarian
carcinoma. Oncol Lett. 4:637–641. 2012.PubMed/NCBI
|
|
24
|
Sharon E, Zhang J, Hollevoet K, et al:
Serum mesothelin and megakaryocyte potentiating factor in
pancreatic and biliary cancers. Clin Chem Lab Med. 50:721–725.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Creaney J, Francis RJ, Dick IM, et al:
Serum soluble mesothelin concentrations in malignant pleural
mesothelioma: relationship to tumor volume, clinical stage and
changes in tumor burden. Clin Cancer Res. 17:1181–1189. 2011.
|
